Umbralisib and Pembrolizumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

NCT03776864 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

6

Enrollment

OTHER

Sponsor class

Stopped Company providing drug terminated their oncology program

Conditions

Hodgkin's Lymphoma

Interventions

BIOLOGICAL: Pembrolizumab
DRUG: Umbralisib

Sponsor

University of Washington

Collaborators

[object Object]